Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02948257 · ClinicalTrials.gov registry record
VASCADE ANTEGRADE-PVD Post-Market Registry
A clinical trial of Surgical Wound, sponsored by Cardiva Medical.
- Completed
- Registry status
- 52
- Enrollment target
- 5
- Study locations
NCT02948257: Completed study of Surgical Wound, sponsored by Cardiva Medical.
NCT02948257 is a study of Surgical Wound that has completed, run by Cardiva Medical. The registered enrollment target is 52 participants, below the 92-participant average among 17 other Surgical Wound trials with a reported enrollment target (43% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02948257, a study of Surgical Wound, has completed, sponsored by Cardiva Medical.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
- 5
- Study locations
Study Summary
The objective of the registry is to collect procedural outcomes data when the Cardiva VASCADE Vascular Closure System (VCS) is used to seal femoral arterial access sites at the completion of ipsilateral peripheral interventional procedures performed through 5-7F introducer sheaths via an antegrade approach.
Primary Outcome
Time to Hemostasis (TTH) is defined as elapsed time between VASCADE device removal and first observed and confirmed arterial hemostasis.
Conditions Studied
Interventions
- DEVICE Cardiva Medical VASCADE VCS
Study Locations (5)
Louisiana
- Cardiovascular Institute of the South - Houma
Mississippi
- North MS Medical Center - Tupelo
North Carolina
- Coastal Surgery Specialists - Wilmington
Ohio
- Cleveland Clinic Foundation - Cleveland
Texas
- San Antonio Endovascular and Heart Institute - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2017-09-18 |
What the finished NCT02948257 record still lists
NCT02948257 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 92-participant average among 17 other Surgical Wound trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Surgical Wound appearing as the primary indexed condition, and to 1 intervention - of which Cardiva Medical VASCADE VCS is the first listed.
NCT02948257 lists 5 locations in 5 states (Louisiana, Mississippi, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02948257 about?
NCT02948257 is a clinical study titled "VASCADE ANTEGRADE-PVD Post-Market Registry". The objective of the registry is to collect procedural outcomes data when the Cardiva VASCADE Vascular Closure System (VCS) is used to seal femoral arterial access sites at the completion of ipsilateral peripheral interventional procedures performed through 5-7F introducer sheaths via an antegrade a...
What is the current status of trial NCT02948257?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2017-01-19. Estimated completion is 2017-09-18.
What conditions does trial NCT02948257 study?
This clinical trial studies the following conditions: Surgical Wound.
What interventions are being tested in trial NCT02948257?
The interventions under investigation include: Cardiva Medical VASCADE VCS (DEVICE).
Who is sponsoring clinical trial NCT02948257?
This trial is sponsored by Cardiva Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02948257 being conducted?
This trial has 5 study locations across Louisiana, Mississippi, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Wound
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02948257's enrollment target sits among peer trials
52 9th of 17 higher than 9 of 17 other Surgical Wound trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgical Wound trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction
RECRUITING · Phase 2
-
Early Versus Delayed Bathing of Orthopaedic Surgical Wounds
RECRUITING · NA
-
A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms
RECRUITING
-
fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
RECRUITING
-
Regenn® Therapy System Safety Study
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI